Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1 infected naïve patients with high CD4 counts Viral tropism by geno2pheno as.

Slides:

Advertisements

Similar presentations

Background  Hypertrigliceridaemia is common in patients with HIV, especially those taking protease inhibitors (PIs) or with lipodystrophy.  Although,

Advertisements

Retention across the continuum of care in a cohort of HIV infected children in rural India G. Alvarez-Uria RDT Hospital, Department of Infectious Diseases,

Prevalence of and Progression to Abnormal Non-Invasive Markers of Liver Disease (APRI and FIB-4) among US HIV-infected Youth Kapogiannis B, Leister E,

Characteristics of clients undergoing repeat HIV counseling and testing compared to clients newly-tested for HIV in Nyanza Province Oyaro P, Owuor K, Ng’eno.

Virologic and immunologic response following antiretroviral therapy initiation among pregnant and postpartum women with acute HIV-1 infection: MOPDB0101.

Institutes: Ukrainian Medical and Dental Academy, Regional HIV/AIDS Prevention and Control Center, Poltava Ukraine Toll-like receptor 4 polymorphism influence.

1 Using Biostatistics to Evaluate Vaccines and Medical Tests Holly Janes Fred Hutchinson Cancer Research Center.

Protective HLA Class I alleles are associated with reduced immune activation in Primary HIV infection Elizabeth Hamlyn 1, Stephen Hickling 2, Abdel Babiker.

ACTG 333 The Antiviral Effect of Switching from Saquinavir to the New Formulation of Saquinavir vs. Switching to Indinavir After >1 year of Saquinavir.

Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.

Mixed HCV Genotype Infection and Response to anti-HCV treatment in HIV/HCV Co-Infected Patients Lucy Porrino, Sabrina Bagaglio, Giulia Morsica, Giulia.

Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.

J.L.K. Fletcher, S. Pinyakorn, M. de Souza, S. Akapirat, R. Trichavaroj, T. Pankam, E. Kroon, D. Colby, P. Prueksakaew, D. Suttichom, J.H. Kim, P. Phanuphak,

Validating five questions of antiretroviral non-adherence in a decentralized public-sector antiretroviral treatment program in rural South Africa Krisda.

De Luca A 1,2, Bracciale L 1, Doino M 1, Fabbiani M 1, Sidella L 1, Marzocchetti A 1, Farina S 1, D’Avino A 1, Cauda R 1, Di Giambenedetto S 1 Safety and.

Is monitoring for CD4 counts still needed for the management of patients with long- term HIV RNA suppression? Andrew Hill, Liverpool University, UK.

Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.

The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected.

Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.

Older and wiser: continued improvements in clinical outcome and highly active antiretroviral therapy (HAART) response in HIV-infected children in the UK.

Increased clinical events in HIV-infected patients who achieve full virologic suppression but fail to attain a CD4 count ≥ 200 cells/mm 3 after one year.

Catherine Kober Margaret Johnson Martin Fisher Caroline Sabin On behalf of UK-CHIC BHIVA/BASHH Manchester 2010 Non-uptake of HAART among patients with.

Background Acknowledgements: Support was provided by NIAID grants U01 AI042170, U01 AI and U01 AI (CPCRA & INSIGHT) and R44AI (NIAID.

Naive CD4 T lymphocytes and recent thymic emigrants, 15 or more years after perinatal HIV infection The ANRS-EP38-IMMIP study Stéphane Blanche, Daniel.

HIV/renal studies (CHIC) Baseline renal function as predictor of HIV/renal disease progression –Death, opportunistic infection –Severe chronic kidney disease.

Impact of Highly Active Antiretroviral Therapy on the Incidence of HIV- encephalopathy among perinatally- infected children and adolescents. Kunjal Patel,

Life expectancy of patients treated with ART in the UK: UK CHIC Study Margaret May University of Bristol, Department of Social Medicine, Bristol.

Poster # 388 CROI Feb Montreal, Canada Association of HIV-1 Co-receptor Tropism with Immunologic and Virologic Parameters in HIV-1 infected,

Generously supported by the Robert Wood Johnson Foundation Clinical Scholars Program, Department of Veteran Affairs, and National Institutes of Health,

Neurocognitive Impairment in HIV-Infected Subjects on HAART: Prevalence and Associations Kevin Robertson *1, Kunling Wu 2, Thomas Parsons 1, Ron Ellis.

Association between CSF and peripheral markers of immune- activation/inflammation and elevated intratechal HIV–RNA levels in a cohort of.

Engagement in the HIV care cascade among transgender women enrolled in a public HIV clinic in Buenos Aires, Argentina, M.E. Socías 1,2, O. Sued.

Factors Associated with Persistent Neurocognitive Impairment Despite Long-term HAART in Patients with HIV-Dementia V Tozzi, P Balestra, MF Salvatori, C.

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500.

Lipoatrophy and lipohypertrophy are independently associated with hypertension: the effect of lipoatrophy but not lipohypertrophy on hypertension is independent.

HBV related complications in HIV positive patients during HAART therapy Irina Magdalena Dumitru*, E. Dumitru*, S. Rugina*, Roxana Carmen Cernat**, Simona.

Glomerular lesions in HIV-1-infected patients: evolution from 1996 to 2007 on 88 consecutive renal biopsies. Clara Flateau, François-Xavier Lescure, Emmanuelle.

N ICOLETTA CICCARELLI 1 1 L OW ADHERENCE AND CD4 NADIR ARE ASSOCIATED TO COGNITIVE PERFORMANCE IN HIV - INFECTED PATIENTS.

Results Compliance with Breast Cancer Screening Guidelines in the HIV Clinic: A Quality Improvement Tool E. Patrozou M.D., E. Christaki M.D., L. Hicks.

Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2006* *Numbers are based on reports received rather than children seen to.

Maintenance therapy with Trizivir® after 6 months induction with Trizivir® plus either efavirenz or lopinavir/r in naïve patients. Trizefal study J. Mallolas*

Progressive histological liver improvement after sustained virological response to therapy in HCV / HIV coinfected patients. Jose L. Casado,

Persistent immune activation despite suppressive HAART is associated with higher risk for viral blips in HIV-1 infected individuals Alexander Zoufaly 1.

Poor linkage to care despite significant improvement in access to early cART – data from Test and Keep in Care (TAK) project. Leah Shepherd, Magdalena.

Background Appropriate time to start HAART is still debatable 1995: “Time to hit HIV, early and hard” Eradication thought to be possible Early regimens.

Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.

Figure 2: Trends in currently prescribed antiretroviral therapy % prescribed HAART increased from 74% to 83% Trends in ART use, HIV viral load, and CD4.

Effect of ART on malaria parasitaemia and clinical episodes in adults in rural Uganda: A population-based cohort study Billy N. Mayanja 1, Kathy Baisley.

HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.

Neurologic Effects Associated With Efavirenz Generally Mild, Transient Slideset on: Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological.

Efavirenz Use Not Associated With Depressive Episodes, According to Analysis of Randomized Clinical Trial Outcomes Slideset on: Journot V, Chene G, De.

HIV co-receptor tropism in treatment-naïve patients: impact on CD4 decline and subsequent response to HAART Laura Waters, Sundhiya Mandalia, Adrian Wildfire,

QUALI DIFFERENZE IN RAPPORTO AL SESSO NELLA COINFEZIONE HCV/HIV? I DATI ITALIANI DALLA COORTE ICONA Antonella Cingolani Clinica Malattie Infettive, UCSC,

The Dynamics of HIV RNA, CD4+ Count and Mycobacterium tuberculosis (Mtb) Antigen Specific Cytokines in TB/HIV Patients Following Successful Tuberculosis.

Seroprevalence, prevalence, type and factors associated with HPV infection at multiple sites in young HIV-positive MSM On behalf of the HPV MAPS Research.

Virological and immunological efficacy of regimen including MVC

ART and toxicities: CNS

Naseem Cassim Lindi Marie Coetzee Debbie Glencross

Better Retention Rates Observed in Patients on Lopinavir than Atazanavir in Uganda

Patients w/AIDS-defining illness

Les Lang Gastroenterology Volume 133, Issue 1, (July 2007)

NRTI-sparing SPARTAN PROGRESS RADAR NEAT001/ANRS 143 A VEMAN

Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following.

Les Lang Gastroenterology Volume 133, Issue 1, (July 2007)

The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients M.M. Santoro, D. Armenia, L. Fabeni,

Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients.

Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD

HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients N. Gianotti,

Andreas D. Haas, PhD Postdoctoral fellow, ICAP at Columbia University

Khai Hoan Tram, Jane O’Halloran, Rachel Presti, Jeffrey Atkinson

Presentation transcript:

Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1 infected naïve patients with high CD4 counts Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1 infected naïve patients with high CD4 counts Nozza S 1, Canducci F 2, Galli L 1, Cozzi-Lepri A 3, Capobianchi MR 4, Ceresola E 2, Antinori A 3,4, Di Giambenedetto S 3,5, D’Arminio Monforte A 3,6, Castagna A 1,3 and ICONA Foundation 1 Department of Infectious Diseases - IRCCS San Raffaele, Milan, Italy 2 Laboraf, San Raffaele Scientific Institute, Milan, Italy 3 ICONA Foundation, Italy 4 IRCCS Spallanzani, Rome, Italy 5 Catholic University, Rome, Italy 6 Azienda Ospedaliera San Paolo, Milan, Italy TUPDB0103

AIM OF THE STUDY To investigate the value of a geno2pheno estimate of viral tropism in predicting CD4+ depletion in HIV-infected naive subjects with high CD4+. Multicenter, cohort study with retrospective assessment of viral tropism on stored plasma samples METHODS  Included HIV-1 naive infected patients with:  CD4+>350 cells/mm 3 at time of first sample  HIV-RNA>500 copies/mL  Follow-up time ranged from the date of first available plasma sample (baseline) to the date of the last visit or the date of cART initiation.  HIV-1 coreceptor usage was determined by algorithm geno2pheno, available at inf.mpg.de/, with a cut-off of false-positive rate (FPR) of 10%.

Baseline characteristics Median values (IQR) or n (%) Characteristics OVERALL (N=223) R5 (FPR>10%) (N=192) Non-R5 (FPR≤10%) (N=31) P value ( R5 vs non-R5) Age at sample collection (years) 35 (31-40)35 (31-41)33 (30-37)0.183 Nationality Italian Other 211 (95%) 12 (5%) 181 (94%) 11 (6%) 30 (97%) 1 (3%) Gender Female Male 86 (39%) 137 (61%) 75 (39%) 117 (61%) 11 (35%) 20 (65%) Risk factor for HIV IVDU Heterosex 99 (44%) 124 (56%) 81 (82%) 111 (90%) 18 (18%) 13 (11%) Calendar year of HIV infection1997 ( )1997 ( )1996 ( )0.139 Nadir CD4+ (cells/µL) 567 ( )575 ( )544 ( )0.893 Months since HIV infection to sample collection22.0 ( )20.2 ( )36.9 ( )0.178 Months since sample collection to the start of cART 16.4 ( )13.9 ( )18.4 ( )0.777 HCVab Negative Positive Unknown 52 (23%) 51 (23%) 120 (54%) 48 (92%) 43 (84%) 101 (84%) 4 (8%) 8 (16%) 19 (16%) CD4+ at sample collection (cells/µL) 571 ( )581 ( )540 ( )0.584 HIV-RNA at sample collection (log10 copies/mL) 4.1 ( ) 4.0 ( )0.343

Median (IQR) CD4+ change: -218 (-281/-143) cells/µL Median (IQR) CD4+ change: -150(-276/0) cells/µL P=0.038 Fig 1 CD4 Decrease according to viral tropism Fig 2 CD4 Decrease according to gender P=0.255 Median (IQR) CD4+ change: -133 (-272/+0.5) cells/µL Median (IQR) CD4+ change: -166(-284/-60) cells/µL

Acknowledgments